Fragile X Syndrome Research Study​

Fragile X Syndrome Research Study

Currently enrolling individuals age 3 to 22 years of age with Fragile X syndrome who are also experiencing behavioural-related issues.

Reconnect Fragile X Syndrome Research Study​ - Zynerba Pharmaceuticals

Why is this Medical Research Study Important?

The purpose of this study is to assess the effectiveness and safety of an investigational treatment for individuals with Fragile X syndrome (FXS).

Individuals with FXS often experience behavioural symptoms such as anxiety (particularly social anxiety/avoidance), irritability, tantrums and social unresponsiveness, which can be challenging, not only for the individuals, but also their families. This investigational treatment may help to reduce these symptoms and has shown potentially promising results in prior studies.

To help us learn more about the safety and effectiveness of an investigational treatment, volunteers are needed for the RECONNECT study. Qualified participants will receive study drug or placebo and will help investigators learn more about FXS.

Qualified Participants Must:

Be between the ages of 3 to 22 years of age.
Have a diagnosis of FXS; with full mutation of the FMR1 gene documented through genetic testing.
Be experiencing behavioural symptoms of Fragile X syndrome such as social anxiety/avoidance, irritability and social unresponsiveness.

Apply today to see if someone you love may qualify for this exciting study!